On 29 December 2000, orphan designation (EU/3/00/013) was granted by the European Commission to Laxdale Ltd., United Kingdom, for ethyl eicosopentaenoate for the treatment of Huntington's disease. The name of the sponsor has since changed to Amarin Neuroscience Ltd.
|Disease / condition||
Treatment of Huntington’s disease
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: